1. Clinical & Scientific Overview
Naproxen (and Naproxen Sodium) (TIP-MED-000107, Reference Code [7.5]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Non-Steroidal Anti-Inflammatory Drug (NSAID); Long-Acting Propionic Acid Derivative.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.5], p. 81): Naprosyn (RPG Life Sciences), Xenobid (Lupin); In FDC with Domperidone (for Migraine): Naxdom 250 / Naxdom 500 (Sun Pharma), Xenodom — Strengths & Dosage Forms: Oral Uncoated / Enteric-Coated Tablets: 250 mg, 500 mg; Sustained-Release: 750 mg SR (Note: 275 mg and 550 mg Naproxen Sodium equal 250 mg and 500 mg Naproxen base)
Oral Uncoated / Enteric-Coated Tablets: 250 mg, 500 mg; Sustained-Release: 750 mg SR (Note: 275 mg and 550 mg Naproxen Sodium equal 250 mg and 500 mg Naproxen base)
3. Mechanism of Action & Pharmacodynamics
Non-Steroidal Anti-Inflammatory Drug (NSAID); Long-Acting Propionic Acid Derivative acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Non-Steroidal Anti-Inflammatory Drug (NSAID); Long-Acting Propionic Acid Derivative for Acute migraine attacks (especially combined with domperidone in Naxdom); acute gout flare; ankylosing spondylitis, rheumatoid arthritis, and osteoarthritis; acute tendinitis/bursitis and dysmenorrhoea..
4. Therapeutic Indications & Evidence-Supported Uses
- Acute migraine attacks (especially combined with domperidone in Naxdom)
- acute gout flare
- ankylosing spondylitis, rheumatoid arthritis, and osteoarthritis
- acute tendinitis/bursitis and dysmenorrhoea
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Arthritis/Pain: 250 mg to 500 mg twice daily (every 12 hours) after meals (Maximum 1000 mg/day; up to 750 mg initial loading in acute gout followed by 250 mg every 8 hours until flare subsides). Follow physician prescription.
Administration & Meal Timing: Take WITH or immediately AFTER breakfast and dinner with a full glass of water. | Twice daily (every 12 hours, morning and evening after food) due to its long elimination half-life (12–17 hours).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Strictly contraindicated if CrCl <30 mL/min (unbound naproxen and metabolites accumulate). Hepatic: Reduce dose by 50% in moderate hepatic disease; avoid in severe cirrhosis.
Renal: Strictly contraindicated if CrCl <30 mL/min (unbound naproxen and metabolites accumulate). Hepatic: Reduce dose by 50% in moderate hepatic disease; avoid in severe cirrhosis.
Renal: Strictly contraindicated if CrCl <30 mL/min (unbound naproxen and metabolites accumulate). Hepatic: Reduce dose by 50% in moderate hepatic disease; avoid in severe cirrhosis.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in active peptic ulcer/GI bleeding, severe heart failure, CrCl <30 mL/min, aspirin-sensitive asthma, and 3rd trimester of pregnancy. Note: While naproxen has the lowest relative myocardial infarction risk among non-selective NSAIDs (due to sustained COX-1 inhibition), it carries a higher intermediate gastrointestinal ulcer/bleeding risk than ibuprofen or celecoxib—mandatory PPI co-therapy in high-risk patients!
Key Clinical Precautions: Renal: Strictly contraindicated if CrCl <30 mL/min (unbound naproxen and metabolites accumulate). Hepatic: Reduce dose by 50% in moderate hepatic disease; avoid in severe cirrhosis.
8. Adverse Effects Profile
- Dyspepsia, heartburn, epigastric pain, nausea, headache, dizziness, drowsiness, pedal oedema, tinnitus.
- Upper and lower GI ulceration, perforation, and bleeding; acute kidney injury; fluid retention/heart failure decompensation; pseudoporphyria/photosensitivity.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Like ibuprofen, naproxen can competitively interfere with low-dose aspirin's platelet COX-1 acetylation if dosed improperly
- Increases bleeding risk with anticoagulants, clopidogrel, SSRIs, and steroids
- Decreases clearance of lithium and methotrexate
- Blunts ACEI/ARB and furosemide efficacy
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Because naproxen lasts a full 12 hours, do not take it more than twice daily (unless specifically directed for day 1 of acute gout). If prescribed Naxdom 500 for migraine, take at the earliest aura/headache onset and remember it contains domperidone (avoid combining with QT-prolonging drugs).
- Meal & Clock Timing Instruction: Take WITH or immediately AFTER breakfast and dinner with a full glass of water. (Twice daily (every 12 hours, morning and evening after food) due to its long elimination half-life (12–17 hours).)
- Missed Dose Protocol: Take with food if remembered; skip if within 6 hours of the next scheduled dose.
- Geriatric Dispensing Pearl: Beers Criteria: Avoid prolonged use in elderly patients. Because elimination half-life extends in old age and hypoalbuminaemia increases free drug fraction, cap dose at 250 mg BD with mandatory Pantoprazole 40 mg OD if short-term use is essential.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated / Enteric-Coated Tablets: 250 mg, 500 mg; Sustained-Release: 750 mg SR (Note: 275 mg and 550 mg Naproxen Sodium equal 250 mg and 500 mg Naproxen base)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.5] (p. 81)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.7] Tramadol Hydrochloride — Weak Centrally Acting Mu-Opioid Receptor Agonist & Serotonin/Nore
- [7.8] Pregabalin — Gabapentinoid; Presynaptic Voltage-Gated Calcium Channel Alpha-2-
- [7.9] Gabapentin — Gabapentinoid; Voltage-Gated Calcium Channel Alpha-2-Delta (α2δ)
- [7.10] Allopurinol — Xanthine Oxidase Inhibitor (Purine Analogue; Metabolised to Activ
